CPHI Fundamental Analysis - CHINA PHARMA HOLDINGS INC

Name: CHINA PHARMA HOLDINGS INC (CPHI) Stock
Brand: CHINA PHARMA HOLDINGS INC
Rating: 0.5 (3 reviews)

Fundamental Rating

Taking everything into account, CPHI scores 1 out of 10 in our fundamental rating. CPHI was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CPHI have multiple concerns. CPHI does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

CPHI had negative earnings in the past year.

CPHI had a positive operating cash flow in the past year.

In the past 5 years CPHI always reported negative net income.

In the past 5 years CPHI always reported negative operating cash flow.

1.2 Ratios

CPHI has a Return On Assets (-26.56%) which is comparable to the rest of the industry.

With a Return On Equity value of -56.58%, CPHI perfoms like the industry average, outperforming 51.56% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-26.56%
ROE	-56.58%
ROIC	N/A

ROA(3y)-24.28%

ROA(5y)-20.29%

ROE(3y)-65.01%

ROE(5y)-57.47%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CPHI has more shares outstanding

CPHI has more shares outstanding than it did 5 years ago.

CPHI has a worse debt/assets ratio than last year.

2.2 Solvency

CPHI has an Altman-Z score of -4.96. This is a bad value and indicates that CPHI is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -4.96, CPHI is not doing good in the industry: 60.42% of the companies in the same industry are doing better.

The Debt to FCF ratio of CPHI is 48.73, which is on the high side as it means it would take CPHI, 48.73 years of fcf income to pay off all of its debts.

The Debt to FCF ratio of CPHI (48.73) is better than 74.48% of its industry peers.

A Debt/Equity ratio of 0.53 indicates that CPHI is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.53, CPHI is not doing good in the industry: 62.50% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.53
Debt/FCF	48.73
Altman-Z	-4.96

ROIC/WACCN/A

WACC6.91%

2.3 Liquidity

A Current Ratio of 0.51 indicates that CPHI may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.51, CPHI is doing worse than 92.71% of the companies in the same industry.

CPHI has a Quick Ratio of 0.51. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.19, CPHI is not doing good in the industry: 93.75% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.51
Quick Ratio	0.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.70% over the past year.

The Revenue for CPHI has decreased by -29.64% in the past year. This is quite bad

The Revenue for CPHI have been decreasing by -16.15% on average. This is quite bad

EPS 1Y (TTM)74.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.84%

Revenue 1Y (TTM)-29.64%

Revenue growth 3Y-22.27%

Revenue growth 5Y-16.15%

Sales Q2Q%10.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CPHI. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CPHI is valued a bit cheaper than the industry average as 76.04% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	75.59
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CPHI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CHINA PHARMA HOLDINGS INC

NYSEARCA:CPHI (11/3/2025, 3:25:30 PM)

1.63

-0.01 (-0.61%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-25 2022-11-25/amc

Earnings (Next)N/A N/A

Inst Owners3.64%

Inst Owner Change0%

Ins Owners19.05%

Ins Owner Change0%

Market Cap5.31M

Revenue(TTM)4.40M

Net Income(TTM)-3656300

Analysts0

Price TargetN/A

Short Float %0.15%

Short Ratio0.13

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.21
P/FCF	75.59
P/OCF	12.51
P/B	0.82
P/tB	242.64
EV/EBITDA	N/A

EPS(TTM)-1.58

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.02

FCFY1.32%

OCF(TTM)0.13

OCFY7.99%

SpS1.35

BVpS1.98

TBVpS0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.56%
ROE	-56.58%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	1.6%

ROA(3y)-24.28%

ROA(5y)-20.29%

ROE(3y)-65.01%

ROE(5y)-57.47%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.32

Health

		Industry Rank	Sector Rank
Debt/Equity	0.53
Debt/FCF	48.73
Debt/EBITDA	N/A
Cap/Depr	19.75%
Cap/Sales	8.06%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.51
Quick Ratio	0.19
Altman-Z	-4.96

F-Score5

WACC6.91%

ROIC/WACCN/A

Cap/Depr(3y)8.82%

Cap/Depr(5y)14.6%

Cap/Sales(3y)3.86%

Cap/Sales(5y)4.82%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)74.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.84%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-29.64%

Revenue growth 3Y-22.27%

Revenue growth 5Y-16.15%

Sales Q2Q%10.91%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y12.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y106.35%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y148.16%

OCF growth 3YN/A

OCF growth 5YN/A

CHINA PHARMA HOLDINGS INC / CPHI FAQ

Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?

ChartMill assigns a fundamental rating of 1 / 10 to CPHI.

What is the valuation status for CPHI stock?

ChartMill assigns a valuation rating of 1 / 10 to CHINA PHARMA HOLDINGS INC (CPHI). This can be considered as Overvalued.

What is the profitability of CPHI stock?

CHINA PHARMA HOLDINGS INC (CPHI) has a profitability rating of 1 / 10.

How financially healthy is CHINA PHARMA HOLDINGS INC?

The financial health rating of CHINA PHARMA HOLDINGS INC (CPHI) is 1 / 10.

CHINA PHARMA HOLDINGS INC (CPHI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CHINA PHARMA HOLDINGS INC / CPHI FAQ

Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?

What is the valuation status for CPHI stock?

What is the profitability of CPHI stock?

How financially healthy is CHINA PHARMA HOLDINGS INC?